Half Year Results 

Dechra's non-pandemic supply issues

Dechra's non-pandemic supply issues

The coronavirus outbreak has highlighted how reliant western businesses are on Asian supply chains. Dechra Pharmaceuticals (DPH) provides a case in point. The veterinary products group doesn’t generate any direct or indirect revenue from China, but a “prolonged period of interruption” would see its own stocks dwindle. There is sufficient inventory to meet near-term demand, but much will depend on how rapidly normal commercial activity resumes in the affected provinces in China.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now